These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 35742910)

  • 21. Genetically engineered human pituitary corticotroph tumor organoids exhibit divergent responses to glucocorticoid receptor modulators.
    Mallick S; Chakrabarti J; Eschbacher J; Moraitis AG; Greenstein AE; Churko J; Pond KW; Livolsi A; Thorne CA; Little AS; Yuen KCJ; Zavros Y
    Transl Res; 2023 Jun; 256():56-72. PubMed ID: 36640905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An individualized approach to the management of Cushing disease.
    Fleseriu M; Varlamov EV; Hinojosa-Amaya JM; Langlois F; Melmed S
    Nat Rev Endocrinol; 2023 Oct; 19(10):581-599. PubMed ID: 37537306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alterations in hypothalamic-pituitary-adrenal function immediately after resection of adrenal adenomas in patients with Cushing's syndrome and others with incidentalomas and subclinical hypercortisolism.
    Khawandanah D; ElAsmar N; Arafah BM
    Endocrine; 2019 Jan; 63(1):140-148. PubMed ID: 30259310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Corticotroph adenoma].
    Guignat L; Assie G; Bertagna X; Bertherat J
    Presse Med; 2009 Jan; 38(1):125-32. PubMed ID: 19041214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucocorticoid inhibition of ACTH peptides: small cell lung cancer cell lines are more resistant than pituitary corticotroph adenoma cells.
    Farrell WE; Stewart MF; Clark AJ; Crosby SR; Davis JR; White A
    J Mol Endocrinol; 1993 Feb; 10(1):25-32. PubMed ID: 8383976
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of ACTH secretion in Cushing's adenoma and clinically silent corticotroph adenoma by cell immunoblot assay.
    Kojima Y; Suzuki S; Yamamura K; Ohhashi G; Yamamoto I
    Endocr J; 2002 Jun; 49(3):285-92. PubMed ID: 12201210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas.
    Katznelson L; Bogan JS; Trob JR; Schoenfeld DA; Hedley-Whyte ET; Hsu DW; Zervas NT; Swearingen B; Sleeper M; Klibanski A
    J Clin Endocrinol Metab; 1998 May; 83(5):1619-23. PubMed ID: 9589666
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas.
    Tateno T; Kato M; Tani Y; Oyama K; Yamada S; Hirata Y
    Endocr J; 2009; 56(4):579-84. PubMed ID: 19318729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cushing's disease and pregnancy.
    Polli N; Pecori Giraldi F; Cavagnini F
    Pituitary; 2004; 7(4):237-41. PubMed ID: 16132201
    [No Abstract]   [Full Text] [Related]  

  • 30. Two Distinctive POMC Promoters Modify Gene Expression in Cushing Disease.
    Araki T; Tone Y; Yamamoto M; Kameda H; Ben-Shlomo A; Yamada S; Takeshita A; Yamamoto M; Kawakami Y; Tone M; Melmed S
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3346-e3363. PubMed ID: 34061962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.
    van der Pas R; Feelders RA; Gatto F; de Bruin C; Pereira AM; van Koetsveld PM; Sprij-Mooij DM; Waaijers AM; Dogan F; Schulz S; Kros JM; Lamberts SW; Hofland LJ
    J Clin Endocrinol Metab; 2013 Dec; 98(12):E1880-90. PubMed ID: 24081741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The ectopic ACTH syndrome].
    Penezić Z; Savić S; Vujović S; Tatić S; Ercegovac M; Drezgićc M
    Srp Arh Celok Lek; 2004; 132(1-2):28-32. PubMed ID: 15227962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nur77 gene expression levels were involved in different ACTH-secretion autonomy between Cushing's disease and subclinical Cushing's disease.
    Tabuchi Y; Kitamura T; Fukuhara A; Mukai K; Onodera T; Miyata Y; Hamasaki T; Oshino S; Saitoh Y; Morii E; Otsuki M; Shimomura I
    Endocr J; 2016 Jun; 63(6):545-54. PubMed ID: 27025408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human adrenocorticotropin-secreting pituitary adenomas show frequent loss of heterozygosity at the glucocorticoid receptor gene locus.
    Huizenga NA; de Lange P; Koper JW; Clayton RN; Farrell WE; van der Lely AJ; Brinkmann AO; de Jong FH; Lamberts SW
    J Clin Endocrinol Metab; 1998 Mar; 83(3):917-21. PubMed ID: 9506748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pituitary-adrenal dynamics after ACTH-secreting pituitary tumor resection in patients receiving no steroids post-operatively.
    Pimentel-Filho FR; Silva ME; Nogueira KC; Berger K; Cukiert A; Liberman B
    J Endocrinol Invest; 2005 Jun; 28(6):502-8. PubMed ID: 16117190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Mechanisms Underlying Autonomous Adrenocorticotropic Hormone Secretion in Cushing's Disease.
    Fukuoka H; Shichi H; Yamamoto M; Takahashi Y
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33266265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High prolactin levels in patients with Cushing's disease without pathological evidence of pituitary adenoma.
    Comtois R; Beauregard H; Hardy J; Robert F; Somma M
    Clin Endocrinol (Oxf); 1993 Jun; 38(6):601-7. PubMed ID: 8392915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elevated post-dexamethasone suppression cortisol concentrations correlate with hormonal alterations of the hypothalamo-pituitary adrenal axis in patients with adrenal incidentalomas.
    Tsagarakis S; Roboti C; Kokkoris P; Vasiliou V; Alevizaki C; Thalassinos N
    Clin Endocrinol (Oxf); 1998 Aug; 49(2):165-71. PubMed ID: 9828902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing's disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone.
    Fleseriu M; Findling JW; Koch CA; Schlaffer SM; Buchfelder M; Gross C
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3718-27. PubMed ID: 25013998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.
    Liu NA; Araki T; Cuevas-Ramos D; Hong J; Ben-Shlomo A; Tone Y; Tone M; Melmed S
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2557-64. PubMed ID: 25942479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.